Atezolizumab (a programmed death-ligand 1, PD-L1 inhibitor) combined with bevacizumab (a monoclonal antibody that targets vascular endothelial growth factor, VEGF) have been reported to significantly prolong the overall and progression-free survival outcomes than sorafenib in patients with unresectable HCC (63). Here, VEGFA is linked to hepatocellular carcinoma.